TopTreat is a large R&D program in which Stichting ReumaNederland, UT, RUMC, various hospitals, Roessingh R&D, two companies and the Ministry of Defense join forces to improve treatment options and quality of life for osteoarthritis patients. Osteoarthritis (wear and tear of the protective cartilage that
protects the ends of bones) will be the most common chronic disease in the Netherlands in 2040 and is associated with high healthcare costs, disability and a significant negative impact on the quality of life of patients. At present, the prediction and treatment options are still limited, the results of existing interventions are suboptimal and the knowledge to tailor the treatment to individual patient profiles is lacking.
Through the TopTreat program, the consortium wants to develop a unique and highly accurate technology platform that should enable advanced phenotyping of patients, joint-on-a-chip technology, ambulatory motion and gait sensor analyses and biomechanical modelling of joint dynamics and cartilage stress levels in order to collect more specific characteristics of osteoarthritis. Data-driven prognostic modelling and artificial intelligence enable the most optimal treatment to be tailored to the needs of individual osteoarthritis patients.
Total budget € 4.7 Million
Contact: Prof.dr.ir. Nico Verdonschot and WP6 coordinator: Dr.ir. Periklis Tzanetis
More recent news
Mon 5 Jan 2026Prof. Massimo Sartori gives invited talk at the 4th Nature Conference on flexible electronics, AI in healthcare in April 8-10, 2026.
Thu 11 Dec 2025Prof.dr.ir. Gabriëlle Tuijthof new chair of Department Biomechanical Engineering
Thu 13 Nov 2025ET UTQ Ceremony
Tue 11 Nov 2025Healthcare never stops — but neither does its emissions. Can we make it greener?
Fri 10 Oct 2025Two cum laude Master's graduations